Mad Hedge Biotech & Health Care Letter
November 28, 2019
Fiat Lux
Featured Trade:
(THE BATTLE FOR YOUR HEART IS ON),
(NOVN), (MDCO), (SNY), (AMGN), (TAK)
The rumors are confirmed. Novartis AG (NOVN) has no plans of sitting out the lucrative heart treatment race. The Swiss biopharma giant made its presence known via a $9.7 billion takeover of The Medicine Company (MDCO), putting Sanofi SA (SNY), Amgen (AMGN), and Regeneron Pharmaceuticals (REGN) on high alert for some major league rivalry.
This takeover signifies the latest attempt by Novartis to redirect the future of the company, which currently has a market value of $203 billion through a number of takeovers, mergers, and disposals.
Novartis will be paying $85 in cash for every share, marking a 24% premium over The Medicine Co.’s recent closing price. In return, Novartis will gain control of the smaller biotech’s experimental cholesterol-lowering injection Inclisiran. This breakthrough treatment is currently being prepared for US approval by the end of 2019. Meanwhile, the company will mark the first quarter of 2020 with an EU filing for the treatment.
The pricey bid puts Novartis at the forefront of a market where at least one drug, high cholesterol treatment Repatha, is projected to give Amgen another blockbuster by 2021. Another similar challenger is Sanofi and Regeneron’s joint cholesterol-lowering drug Praluent. So far, these companies have been pounding away to carve out markets with steep prices.
Unfortunately, payer resistance fueled by the estimated patient population affected has been dragging their sales revenue. To add to that, prices for both medications have been limited to somewhere around $6,000 annually.
This is where Novartis’ partnership with The Medicines Company comes in handy.
To be effective, Inclisiran is only needed to be injected twice yearly to patients. This is a far cry from the 26-injection procedure required by both Amgen’s Repatha and Sanofi and Regeneron’s Praluent. The key to Inclisiran’s potency is a technology involving gene silencing or RNA interference, which basically limits “bad cholesterol” production.
Needless to say, Novartis offers an attractive option to over 58 million patients in the United States alone who cannot keep their “bad cholesterol” at bay given the current standard of care. If it gains approval, the company is looking at annual peak sales of roughly $4 billion, with Inclisiran expected to start contributing to their revenue by 2021.
Apart from that, Inclisiran is anticipated to complement Novartis’ existing combination heart failure drug Entresto, which topped the $1 billion yearly revenue threshold in 2018.
Entresto isn’t the only foray of Novartis in the cardiovascular market. Prior to this blockbuster drug, the company led the sector with high blood pressure medication Diovan, which used to rake in $6 billion annually until 2012 when it lost its patent protection.
Now, Novartis appears to be ensuring that history does not repeat itself. That is, the company has been actively seeking acquisitions in an effort to bolster its drug pipeline and portfolio with promising products and groundbreaking technologies.
While this latest deal with The Medicines Company sounds promising, Novartis remains on guard as it looks for alternatives, especially with the upcoming patent expirations of some of its main moneymakers like eye medication Lucentis, genetic blood disorder drug Exjade, and multiple sclerosis treatment Gilenya.
This deal with The Medicines Co fits hand-in-glove with the type of diversification and development projects that Novartis has been pursuing as of late. These deals include the $8.7 billion AveXis (AVXS) agreement, which allowed Novartis access to a landmark gene therapy for spinal muscular atrophy.
Prior to that, the giant biopharma acquired nuclear medicines business Advanced Accelerator Applications (AAAP) for $3.9 billion in 2017. A $2.1 billion deal with target cancer therapy maker Endocyte (ECYT) followed in 2018. Earlier this year, Novartis completed its $5.3 billion acquisition of dry eye treatment Xiidra from Takeda Pharmaceutical (TAK). So far, the Swiss giant has already spent $27.5 billion in its deal spree — and the company isn’t going to stop anytime soon.
I know I’ve said this already, but keep buying (NOVN) on dips.
Mad Hedge Biotech & Healthcare Letter
November 26, 2019
Fiat Lux
Featured Trade:
(WHY KARUNA THERAPEUTICS IS THE BIG ONE THAT GOT AWAY),
(KRTX)
In many respects, buying the shares of small biotech companies is a lot like purchasing lottery tickets. Look no further than Karuna Therapeutics (KRTX), which has just soared sevenfold on the back of wildly successful phase II trials for its schizophrenia drug KarXT.
While it is too late to buy (KRTX), it is illustrative of what is going on in the space with ever-increasing frequency. And the great news for you and me is that biotech is only months into a meteoric move that could last for decades.
KarXT is the next “gamechanger” in the field of schizophrenia. Why is this important? In the United States alone, schizophrenia already affects roughly 2.7 million people or almost 1% of the population. Needless to say, this condition makes handling relationships and maintaining jobs virtually impossible.
With its tendency to become a recurring condition as one of its key defining features, schizophrenics need recurring treatment as well. To make matters worse, the conditions are distinct from one patient to another. Hence, it no longer comes as a surprise that over a third of people afflicted by this condition do not respond to the antipsychotic treatments available in the market today.
As for the treatments that do take effect, the side effects associated with the drugs also hinder the day-to-day activities of the patients causing them to discontinue taking it altogether. Currently, one of the most popular antipsychotic drugs used to treat schizophrenics is Johnson and Johnson’s (JNJ) Invega Sustenna. Based on its 2019 revenues so far, the drug is projected to be on pace to hit the projected sales of $3.3 billion by the fourth quarter.
In comparison, Karuna’s KarXT functions on muscarinic receptors that respond to acetylcholine, which is basically an organic chemical found in the brain. Meanwhile, JNJ’s drugs focus on dopamine and serotonin receptors. This primary difference between the two drugs puts Karuna’s drug on the lead. However, Karuna is not the first in looking into muscarinic receptors. In 2016, Allergan (AGN) paid Heptares Therapeutics $3.3 billion in an effort to license drugs similar to KarXT.
What really inspired excitement though is the tolerability of KarXT. Since the majority of antipsychotic drugs on the market today are notorious for their adverse effects, Karuna’s drug achieved a discontinuation rate of only 20% — an impressive result considering that the placebo group had a 21% discontinuation rate. More impressively, KarXT users did not experience any of the commonly feared side effects like weight gain or drowsiness.
Aside from schizophrenia, Karuna is also looking into ways to use KarXT as a treatment option for other CNS disorders that can offer none of the debilitating side effects of current antipsychotic drugs. This could cover treatments for Alzheimer’s disease and even for pain management.
Following this exciting revelation, Karuna announced its intention to conduct a public offering of 2.6 million shares in an effort to raise additional capital. All things considered, the small biotech company has been moving at a notable pace. Just last June, this PureTech-backed company opened with a $75 million IPO — a humongous jump from its initial price point of $42 million.
So far, the companies competing in the same space as Karuna are Novus Biologicals, Anavex, and TheraVida.
The next important step for Karuna is its meeting with the FDA in the second quarter of 2020, which is anticipated to push KarXT to Phase 3 of its clinical trial. If all goes well, this phase will be launched in the latter part of 2020.
Volatility is always to be expected particularly when investing in biotech companies. Karuna’s amazing news demonstrates why volatility can sometimes be a good thing. Although there are more trials and testing to be performed, the results of KarXT’s study should put Karuna on the hot list of biotech investors.
While this one got away, the Mad Hedge Biotechnology and Healthcare letter has a long list of letters coming promising similar potential.
Mad Hedge Biotech & Healthcare Letter
November 21, 2019
Fiat Lux
Featured Trade:
(WHY VERTEX HAS BEEN ON FIRE),
(VRTX), (CRSP)
Vertex Pharmaceuticals Inc. (VRTX) is the unequivocal king of the genetically rare lung condition cystic fibrosis (CF). To further prove its stronghold of the market, the company recently received FDA approval for its fourth CF treatment called Trikafta — five full months ahead of schedule and merely three months following the company’s application.
In a few weeks, the drug will be available in pharmacies, carrying a price tag of $311,000. This puts Trikafta somewhere in the range of another prized Vertex CF treatment, Kalydeco.
Sales of this newest drug is estimated to reach $4.6 billion by 2023 and more than $6.6 billion by 2025, with the drug projected to hit its peak at $10 billion by the second half of 2020. Hence, this latest addition to Vertex’s pipeline practically guarantees the company’s supremacy over the lucrative multi-billion dollar sector for the next decade or so. More importantly, sales from this CF drug could — at the very least — double the annual revenue of Vertex.
The projected earnings of Trikafta places it in the blockbuster tier as early as 2020, with the drug anticipated to be marketed as a treatment with a “whole new level” of efficacy compared to the earlier CF medications released by Vertex. With this new addition, the company can now reach 90% of CF patients in the United States — a huge leap from 50% it’s currently allowed to treat.
However, the launch of Trikafta is a bittersweet deal with Vertex as sales of older treatments are anticipated to weaken. In particular, the company expects Symdeko and Orkambi to eventually fade away from the market as more and more patients opt for the newer and more potent Trikafta.
Despite the impending success of Trikafta, it appears that Vertex has no intention of letting up. Since its CF products have translated into healthy profits in the past four quarters and a whopping $950 million in the third quarter alone, it’s no wonder the company continues to work on new offerings for this market.
Even with the weakening sales of Symdeko, the performance of the CF drugs in the most recent earnings report showed a 21% jump over the same period in 2018. To date, the company has three additional treatments submitted for Phase II trials.
Beyond the CF realm, Vertex has also been looking to expand in other sectors. One of its exciting partnerships is with gene-editing company CRISPR Therapeutics (CRSP). The two companies have been working closely to come up with game-changing treatments that could pioneer therapies for rare conditions like sickle cell disease, Duchenne muscular dystrophy, and beta thalassemia. All three of these orphan designation drugs have the potential to turn into blockbuster treatments.
For 2019, Vertex projects a product revenue somewhere between $3.70 billion to $3.75 billion. Meanwhile, its full-year earnings per share is estimated to be $4.77, which is a 17% increase from last year’s report.
A clear downside of Vertex is the fact that it’s one of the most highly valued stocks in the biotech industry at 31.1 times forward earnings. Nonetheless, a long-term study of the company’s performance would show that the shares are actually grossly undervalued even at their present-day levels. After all, this biotech stock has the potential to triple or even quadruple its yearly revenue over the next five years or so especially if its partnership with CRISPR Therapeutics comes into fruition.
Overall, the growth and profitability profile of Vertex makes it an attractive stock to own. Add to that its promising pipeline, and you have one of the most attractive names in the biotech sector. Hence, now is the ideal time for investors to buy Vertex shares as you can confidently bet on its dominance on the CF market as well as its exciting gene-editing ventures and potential revenue stream.
Don’t chase Vertex up here but buy the next substantial dip.
Mad Hedge Biotech & Healthcare Letter
November 19, 2019
Fiat Lux
Featured Trade:
(TAKE A WALK ON THE WILD SIDE WITH GENE EDITING),
(EDIT), (NTLA), (CRSP), (VRTX), (REGN), (NOVN)
No other industry has inspired fear as much as the biotech world, and no other sector of the biotech industry has garnered such mixed reactions as the gene-editing group.
At the moment, the public has been grossly undervaluing the three major companies that actually hold the power to control the foundational patents for CRISPR-CAS9 — the gene-editing technique with the greatest potential to dominate the biotech industry. These overlooked Big 3 companies are Editas (EDIT), Intellia Therapeutics (NTLA), and CRISPR Therapeutics (CRSP).
There are distinct differences between these three pioneering biotech firms. With a market value of $2.7 billion, Crispr Therapeutics (CRSP) is the first company to venture into clinical trials, attracting Vertex Therapeutics (VRTX) as one of its major investors. Editas, which has a market cap of $1.3 billion, is a close second to Crispr Therapeutics in terms of clinical trials. Despite the issues plaguing its executive department lately, the company is anticipated to eventually land a big partner to help fund its research as well.
Then there’s Intellia Therapeutics (NTLA). The company, which has a market cap of $850 million, is considered the laggard in the CRISPR gene-editing world. What further fuels the ambivalence of investors is the expectation that clinical trials for its lone drug candidate won’t be ready until 2020 or even 2021. The lack of flashy updates from Intellia Therapeutics has several investors wondering if this low market cap company is actually a good buy.
In its third-quarter earnings report though, Intellia Therapeutics posted revenues worth $10.62 million — a jump from the $7.41 million recorded during the same period in 2018. Aside from that, the company managed to attract Novartis AG (NOVN) as one of its major investors. Recently, the company also established a partnership with Regeneron Pharmaceuticals (REGN), which is viewed as a promising step towards bolstering Intellia Therapeutics’ growth.
Based on their recent updates, Regeneron and Intellia Therapeutics are working on NTLA-2001. This is a treatment for a rare disease called transthyretin amyloidosis (ATTR), also known as a protein misfolding disorder which causes an abnormal protein buildup in the body’s organs and tissues.
While this has yet to reach human trials, the preclinical studies involving non-human primates showed an over 95% reduction of the protein in the patient’s liver. Since this disease requires chronic dosing throughout the lifetime of the patient, the success of NTLA-2001 has an incredible disruptive potential for one-shot treatments of ATTR. Apart from that, this treatment will position Intellia Therapeutics as the sole dominating force in this gene-silencing sector.
As things stand today, Intellia Therapeutics may seem as if it has been straggling behind Crispr Therapeutics and Editas. However, the promising plans of the company may prove this statement false. While its move to take its time before pulling the trigger on NTLA-2001 may be frustrating for investors eager to see the results, the recent developments show that this was a necessary precautionary measure to protect the company’s potentially revolutionary delivery system. Despite the delay, this move could translate to dividends across all the drugs and treatments in Intellia Therapeutics’ pipeline in the next years.
Despite their status of being on the verge of discovering treatments for the incurable diseases, it’s baffling to watch how investors continue to sidestep these Big 3 companies, which have a measly $5 billion valuation among all three of them.
Gradually though, a number of forward-thinking investors are starting to shift out of growth names and turn into more defensive investment strategies. With this switch in style slowly making its way to the public, more and more biotech stocks are revealed to be extremely undervalued — and it’s only a matter of time before the likes of Crispr, Editas, and Intellia become a household name among investors.
While the biotech industry can be a scary place to invest in, the key to succeeding in this sector is understanding the market. It’s also advisable to diversify your portfolio. However, bear in mind that not all portfolios chock full of trials in their pipeline guarantee success. At times, a company only needs one or two promising treatments that can eventually serve as the stepping stone to 30 or more moneymakers.
Buy Intellia Therapeutics on dips, as it is the cheapest of the lot.
Mad Hedge Biotech & Healthcare Letter
November 14, 2019
Fiat Lux
Featured Trade:
JUMP ON THE ASTRAZENECA BANDWAGON
(AZN)
AstraZeneca plc (AZN) has shown a dramatic turnaround over the past three years, crushing its close competitors in the big biopharma landscape. Posting growth for the fifth straight quarter for both profit and sales, the stock has gained more than 10% in the run-up to its latest earnings report.
This pushed the company’s total stock market gains for 2019 to a stellar 33.4%. From a forward-looking price-to-earnings perspective though, investors must remain cautious as the stock also now sports a high valuation.
One of the reasons for the stock’s soaring performance this year is the promising cancer drug lineup, which is the result of AstraZeneca’s risky move to splurge on the development of these products way back in 2014.
Now, although no hard data has been disclosed to the public to date, AstraZeneca’s oncology lineup has been pegged to give Merck & Co.’s (MRK) Keytruda and Bristol-Myers Squibb Co.’s (BMY) Opdivo a run for their money in the lucrative lung cancer drug market.
AstraZeneca is anticipated to release survival data by 2020, with its acquired company Pearl Therapeutics taking charge of testing the effectiveness of Imfinzi to treat non-small cell lung cancer. The robust competition presented by both Bristol’s Opdivo and AstraZeneca’s Imfinzi is projected to carve out $2.5 billion from the sales of Merck’s cash cow Keytruda from 2021 to 2028.
Aside from Imfinzi, AstraZeneca has also raked in increasing revenue from another NSLC drug Tagrisso and ovarian cancer medication Lynparza.
Sales of AstraZeneca’s cancer drugs jumped 48% to hit $2.3 billion in the third quarter of 2019. In the first half of the year, total revenue from the company’s oncology lineup alone soared 52% year over year.
AstraZeneca’s largest moneymaker at the moment, Tagrisso, contributed more than $1.4 billion in the first six months of the year, jumping by 86% compared to the same period in 2018. The surge brought about by this strong cancer drug lineup resulted in a 16% rise in the company’s earnings in the third quarter, hitting $6.1 billion.
While these results are impressive, AstraZeneca’s cancer drug sales have yet to reach their peak. As impressive as Tagrisso has been in the first half of 2019, the other two cancer drugs of the company are actually outperforming this product.
One is Imfinzi, which saw its sales skyrocket by 248% during the same period, raking in $633 million. Meanwhile, Lynparza sales practically doubled to reach $520 million.
While its US sales remain competitive with the company achieving 17% revenue growth, AstraZeneca’s initiatives to expand to the Chinese market have also started to pay off. In fact, earnings from this East Asian country account for almost a fifth of the company’s revenue.
Sales in China continued its positive streak, rising 40% to reach $1.28 billion. To sustain this momentum and strengthen its stronghold in the market, the company recently announced its move to invest $1 billion to develop healthcare startups in the Middle Kingdom. This makes AstraZeneca the latest biopharma behemoth to place a bet on the second-biggest pharmaceuticals market in the world.
With all these in mind, it’s almost impossible to handicap the long-term outlook for AstraZeneca. The company currently has an impressive nine-drug lineup all set to turn into blockbusters this year.
Although the loss of patent exclusivity for cardiovascular disease moneymaker Crestor definitely affected the company, its move to transform its cancer drugs into core growth drivers has been quite successful thus far.
Bolstering its pillars of growth is AstraZeneca’s focus on building on its high-value lung cancer lineup particularly on Imfinzi and Tagrisso. Its emerging cardiovascular drug line has also been garnering attention, making heart medication Brilinta and diabetes treatment Farxiga the next blockbusters for the company.
On top of these, AstraZeneca has been actively developing potent combinations involving mantle cell lymphoma treatment Calquence and Lynparza. Needless to say, the company’s clinical pipeline has presented itself as one of the most promising in the biotech world today.
From where things stand at the moment, AstraZeneca appears to be vindicated in fighting for its standalone strategy and pushing back from the $118 billion hostile takeover attempt of Pfizer in 2014.
In increasing its footprint in emerging markets, AstraZeneca has transformed itself into a biotech company with the potential to dominate the industry in the years to come.
Buy AstraZeneca with both hands on the next dip.
